Information intended for UK healthcare professionals and relevant NHS decision-makers only.
This formulary decision guide was developed from content provided by MSD UK Ltd in a format developed by Guidelines in Practice.
- Ertugliflozin is indicated in adults (≥18 years of age) with type 2 diabetes mellitus, as an adjunct to diet and exercise to improve glycaemic control1
- Ertugliflozin significantly reduced HbA1c, body weight*, and systolic blood pressure* compared with placebo and reductions were sustained over the course of the VERTIS clinical trial programme2,3
- Switching eligible patients on other SGLT-2 inhibitors to Steglatro® could generate estimated potential annual savings of £28,802 per 100,000 people, and of £84,512 for an average CCG (see assumptions).†
* Ertugliflozin is not indicated for body weight or systolic blood pressure reduction
- Ertugliflozin is indicated in adults (≥18 years of age) with type 2 diabetes mellitus, as an adjunct to diet and exercise to improve glycaemic control:1
- as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes.
- The recommended starting dose of ertugliflozin is 5 mg once daily—the dose can be increased to 15 mg once daily if additional glycaemic control is needed1
- Renal impairment:1
- do not initiate in patients with an eGFR < 60 ml/min/1.73m2 or creatinine clearance (CrCl) < 60 ml/min
- discontinue when eGFR is persistently < 45 ml/min/1.73m2 or CrCl is persistently < 45 ml/min
- When ertugliflozin is used in combination with insulin or an insulin secretagogue, a lower dose of insulin or of the insulin secretagogue may be required to reduce the risk of hypoglycaemia1
- In patients with volume depletion, correcting this condition prior to initiation of ertugliflozin is recommended.1
- The VERTIS-CV trial achieved its primary endpoint of non-inferiority for major adverse cardiovascular events compared with placebo in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular (CV) disease (Hazard ratio [HR]: 0.97 [95.6% CI: 0.85–1.11], p < 0.001)4
- The key secondary endpoints were not met. Statistical significance was not reached for the secondary composite endpoint of CV death or hospitalisation for heart failure (HHF); no further testing could be performed due to the hierarchical statistical testing method employed4
- HHF was a pre-specified secondary endpoint but did not have an associated hypothesis and was not part of the hierarchical statistical plan; a relative risk reduction of 30% was observed (absolute risk reduction = 1.1%, 2.5% pooled ertugliflozin group vs 3.6% placebo) (HR: 0.70 [95% CI: 0.54–0.90])4
- Ertugliflozin was generally well tolerated, with a safety profile consistent with the SGLT-2 inhibitor class4
- The incidence of adverse events, serious adverse events, and discontinuation due to adverse events was similar between ertugliflozin and placebo treatment arms, consistent with that observed across the VERTIS programme4
- The incidences of symptomatic hypoglycaemia, hypovolemia, pancreatitis and bone fracture were low and similar in the ertugliflozin and placebo treatment arms4
- No adverse events of Fournier’s gangrene were reported4
- The frequencies of urinary tract infections and genital mycotic infections were higher with ertugliflozin vs. placebo4
- The incidence of amputations, was numerically higher with ertugliflozin vs. placebo.4
- Ertugliflozin offers an opportunity to realise cost savings when prescribing an SGLT-2 inhibitor
- Ertugliflozin list price is approximately 20% lower than all other SGLT-2 inhibitors5
|SGLT-2 inhibitor||28 days supply5|
- In 2020, 7659 packs of SGLT-2 inhibitors were used per 100,000 people at the cost of £36.59 per pack;5,6 this represents a cost of £146,575 in patients without established cardiovascular disease (eCVD) and with estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73m2. Switching patients to ertugliflozin could generate estimated potential savings of £28,802 per 100,000 people and £84,512 for an average clinical commissioning group (CCG)†
- Estimate the potential savings for your CCG using this budget impact model (this link will take you to an MSD promotional website).
† The costs were calculated using the following data:
a. annual sales of SGLT-2 inhibitors, excluding ertugliflozin (2020) = 5,146,810 in the UK
b. current costs at £36.59 per pack5
c. Steglatro® costs at £29.40 per pack5
d. type 2 diabetes mellitus population without established cardiovascular disease and estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73m2 = 52.3%7
e. median CCG population = 293,4238
Evidence for use
- Ertugliflozin provides significant HbA1c reductions as well as body weight and systolic blood pressure reductions, consistent across the VERTIS clinical trial program2,3,9,10
- Steglatro® is not licensed for body weight or blood pressure reduction.
|Placebo-adjusted LS mean reduction from baseline at week 26:|
|Therapy and study||Dose (mg)||HbA1c (%)||Body weight (Kg)||Systolic blood pressure (mmHg)|
*superiority over placebo not statistically significant
- Ertugliflozin should not be used in patients with type 1 diabetes mellitus1
- Very common reported adverse reactions are vulvovaginal mycotic infections and other female genital mycotic infections1
- Common adverse events include: balanitis candida and other male genital mycotic infections, hypoglycaemia, volume depletion, increased urination, vulvovaginal pruritus, thirst, serum lipids changed, haemoglobin and blood urea nitorgen increase1
- Serious diabetic ketoacidosis occurs rarely1
- Ertugliflozin may add to the diuretic effect of diuretics and may increase the risk of dehydration and hypotension1
- Ertugliflozin may increase the risk of hypoglycaemia when used in combination with insulin and/or an insulin secretagogue; therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with ertugliflozin1
- Please refer to the summary of product characteristics for a full list of safety information.1
- Merck Sharp & Dohme Limited. Steglatro film-coated tablets—summary of product characteristics. March 2021.
- Pratley at al. Diabetes Obes Metab 2018; 20 (3): 1111–1120.
- Rosenstock J et al. Diabetes Obes Metab 2018; 20 (3): 520–529.
- Cannon C et al. N Engl J Med 2020; 383: 1425–1435.
- NHS Business Services Authority. Drug Tariff 2021. www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff
- IQVIA. Retail dispensing audit—units MAT. December 2020.
- Lautsch D et al. Diabetes Ther 2019; 10: 2131–2137.
- Office for National Statistics. Clinical commissioning group population estimates (National Statistics); Mid-2019: SAPE22DT6a. Available at: www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/clinicalcommissioninggroupmidyearpopulationestimates
- Terra S et al. Diabetes Obes Metab 2017; 19 (5): 721–728.
- Dagogo-Jack S et al. Diabetes Obes Metab 2018; 20 (3): 530–540.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to MSD, UK (Tel: 0208 1548 000). By clicking the above link you will leave the MSD website and be taken to the MHRA website.
Date of preparation: July 2021